What this is
- How it works
- How it works isn't classified yet
- Tested for
- COVID-19, SARS-CoV-2
- Main trialPhase 2/3
- “The study is a multicenter, adaptive, randomized, double-blinded and placebo-controlled Phase II/III clinical trial. It will be conducted at selected investigational sites globally. The study is comprised of 2 parts.”In the company’s words, NCT04709328 on ClinicalTrials.gov
Other drugs for COVID-19
- MaravirocHealthBio, Inc. · Phase 2/3
- REGENECYTEStemCyte, Inc. · Phase 3
- VYD2311Invivyd, Inc. · Phase 3
- SecutrelvirShionogi · Phase 3
- IbuzatrelvirPfizer · Phase 3
- TozorakimabAstraZeneca · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Not yet recruiting | 1 Jan 2022 | To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19 | |
| Phase 2/3Unknown | 25 May 2021 | The Safety and Efficacy of SCTA01 Against COVID-19 in Patients Admitted to High Dependence or Intensive Care | |
| Phase 2/3Terminated | 29 Dec 2021 | The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19 | |
| Phase 1Completed | 17 Nov 2020 | Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026